Treatment With Pazopanib for Neoadjuvant Breast Cancer

Overview[ - collapse ][ - ]

Purpose The purpose of this study is to determine whether the treatment of a doxorubicin in combination with cyclophosphamide followed by a combination of pazopanib in combination with paclitaxel prior to surgery results in a pathological complete response in females with breast cancer.
ConditionNeoplasms, Breast
InterventionDrug: doxorubicin + cyclophosphamide
Drug: paclitaxel + pazopanib
Procedure: surgery
Drug: pazopanib monotherapy
PhasePhase 2
SponsorGlaxoSmithKline
Responsible PartyGlaxoSmithKline
ClinicalTrials.gov IdentifierNCT00849472
First ReceivedFebruary 12, 2009
Last UpdatedJanuary 30, 2014
Last verifiedDecember 2013

Tracking Information[ + expand ][ + ]

First Received DateFebruary 12, 2009
Last Updated DateJanuary 30, 2014
Start DateJuly 2009
Estimated Primary Completion DateApril 2013
Current Primary Outcome MeasuresNumber of Participants With Pathologic Complete Response (pCR) in the Breast and Nodes [Time Frame: From the start of the study until the time of surgery (average of 221.9 days [standard deviation of 23.65 days] after study entry)] [Designated as safety issue: No]pCR was defined as no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel node identified after neoadjuvant chemotherapy.
Current Secondary Outcome Measures
  • Number of Participants With Pathologic Complete Response (pCR) in the Breast [Time Frame: From the start of the study until the time of surgery (average of 221.9 [standard deviation of 23.65 days] days after study entry)] [Designated as safety issue: No]pCR was defined as no histologic evidence of invasive tumor cells in the surgical breast specimen.
  • Number of Participants With Clinical Complete Response (cCR) in the Breast and Nodes at the Completion of the Doxorubicin and Cyclophosphamide (AC) Period [Time Frame: From the start of the study until an average of 86.2 days (standard deviation of 5.76 days) after study entry] [Designated as safety issue: No]cCR was determined by tumor assessments performed by palpation. All clinical response assessments were to be performed by physical examination of the breast and the axilla. cCR was defined as the resolution of all target and non-target lesions identified at Baseline and no new lesions or other signs of disease progression. The criteria to be used for the determination of progressive disease were at the investigator's discretion.
  • Number of Participants With Clinical CR (cCR) in the Breast and Nodes at the Completion of the AC and Weekly Paclitaxel (WP) + Pazopanib Preoperative Periods [Time Frame: From the start of the study until the preoperative evaluation (an average of 203.0 days [standard deviation of 23.19 days] after study entry)] [Designated as safety issue: No]cCR was determined by tumor assessments performed by palpation. All clinical response assessments were to be performed by physical examination of the breast and the axilla. cCR was defined as the resolution of all target and non-target lesions identified at Baseline and no new lesions or other signs of disease progression. The criteria to be used for the determination of progressive disease were at the investigator's discretion.
  • Invasive Recurrence-free Interval (IRFI) [Time Frame: up to 24 months after study entry] [Designated as safety issue: No]IRFI was assessed as the time from study entry until the diagnosis of the first invasive local (evidence of invasive/in situ breast cancer [except LCIS] in the ipsilateral breast [IB]/skin of the breast), regional (development of tumor in the ipsilateral [IP] internal mammary, IP supraclavicular, IP infraclavicular, and/or IP axillary nodes, as well as the soft tissue of the IP axilla, following surgery), or distant (evidence of tumor in all areas, with the exception of those described for local and regional recurrence) breast cancer recurrence during the 24 months after study entry.
  • Number of Participants With Cardiac Toxicity (Per Common Terminology Criteria for Adverse Events Version 3) at the Completion of the AC Period [Time Frame: From the start of the study until the preoperative evaluation (an average of 86.2 days [standard deviation of 5.76 days] after study entry)] [Designated as safety issue: Yes]The number of participants with cardiac toxicity was defined as those who had cardiac events of Grades (G) 3 and 4 leftventricular dysfunction (LVD) (CTCAE Version 3.0) and/or who had definite or probable cardiac death. Grade refers to the severity of the AE: G 1, mild AE; G 2, moderate AE; G 3, severe AE; G 4, life-threatening/disabling AE; G 5, death related to the AE. A G3 LVD event is defined as symptomatic congestive heart failure (CHF) responsive to intervention. A G4 event is defined as poorly controlled refractory CHF; ventricular assist device or heart transplant indicated.
  • Number of Participants With Cardiac Toxicity (Per CTCAE Version 3) at the Completion of the AC and Weekly Paclitaxel (WP) + Pazopanib Preoperative Periods [Time Frame: From the start of the study until the preoperative evaluation (an average of 203.0 days [standard deviation of 23.19 days] after study entry).] [Designated as safety issue: Yes]The number of participants with cardiac toxicity was defined as those who had cardiac events of Grades (G) 3 and 4 leftventricular dysfunction (LVD) (CTCAE Version 3.0) and/or who had definite or probable cardiac death. Grade refers to the severity of the AE: G 1, mild AE; G 2, moderate AE; G 3, severe AE; G 4, life-threatening/disabling AE; G 5, death related to the AE. A G3 LVD event is defined as symptomatic congestive heart failure (CHF) responsive to intervention. A G4 event is defined as poorly controlled refractory CHF; ventricular assist device or heart transplant indicated.
  • Number of Participants With Cardiac Toxicity (Per CTCAE Version 3.0) During the Postoperative Pazopanib Period [Time Frame: From the start of the study until the end of the postoperative pazopanib period, which coincides with the start of the end of treatment period (an average of 310.8 days [standard deviation of 85.29 days] after study entry)] [Designated as safety issue: Yes]The number of participants with cardiac toxicity was defined as those who had cardiac events of Grades (G) 3 and 4 leftventricular dysfunction (LVD) (CTCAE Version 3.0) and/or who had definite or probable cardiac death. Grade refers to the severity of the AE: G 1, mild AE; G 2, moderate AE; G 3, severe AE; G 4, life-threatening/disabling AE; G 5, death related to the AE. A G3 LVD event is defined as symptomatic congestive heart failure (CHF) responsive to intervention. A G4 event is defined as poorly controlled refractory CHF; ventricular assist device or heart transplant indicated.
  • Participants With Normal Thyroid Stimulating Hormone (TSH) Levels at Baseline Who Had an Elevated TSH Level at Least Once During the Study and During the Individual Study Periods [Time Frame: up to 24 months after study entry] [Designated as safety issue: No]The number of participants with normal thyroid function at Baseline who had an elevation in TSH during the study were recorded. TSH elevation was derived based on local laboratory ranges.
  • Number of Participants With the Indicated Radiotherapy-related Complications [Time Frame: up to 24 months after study entry] [Designated as safety issue: No]
  • Number of Participants With Recurrence Events [Time Frame: up to 24 months after study entry] [Designated as safety issue: No]The number of participants with recurrence events during the 24 months after study entry are reported. A recurrence event is defined as invasive local (evidence of invasive/in situ breast cancer [except LCIS] in the ipsilateral breast [IB]/skin of the breast), regional (development of tumor in the ipsilateral [IP] internal mammary, IP supraclavicular, IP infraclavicular, and/or IP axillary nodes, as well as the soft tissue of the IP axilla, following surgery), or distant (evidence of tumor in all areas, with the exception of those described for local and regional recurrence) breast cancer recurrence during the 24 months after study entry.

Descriptive Information[ + expand ][ + ]

Brief TitleTreatment With Pazopanib for Neoadjuvant Breast Cancer
Official TitleA Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Brief Summary
The purpose of this study is to determine whether the treatment of a doxorubicin in
combination with cyclophosphamide followed by a combination of pazopanib in combination with
paclitaxel prior to surgery results in a pathological complete response in females with
breast cancer.
Detailed Description
This is a phase II non-randomized, multi-center study aimed to evaluate the efficacy and
safety of the combination of pazopanib and paclitaxel following treatment with
cyclophosphamide and doxorubicin for the treatment of neoadjuvant breast cancer.

Patients will receive standard doses of AC every 21 days for 4 cycles. This will be followed
by weekly paclitaxel 80 mg/m2 IV on Days 1, 8, and 15 every 28 days for 4 cycles given
concurrently with pazopanib 800 mg PO daily starting with the first paclitaxel dose and
continuing until 7 days before surgery. Clinical complete response rate will be determined
by tumor assessments performed by palpation at two time points: following AC (before
paclitaxel/pazopanib begins) and 2-4 weeks following the last dose of paclitaxel (before
surgery). Following recovery from preoperative therapy, patients will undergo the
clinically-indicated surgery. Pazopanib will resume 4-6 weeks after surgery and continue
daily for 6 months of postoperative pazopanib therapy.
Study TypeInterventional
Study PhasePhase 2
Study DesignAllocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
ConditionNeoplasms, Breast
InterventionDrug: doxorubicin + cyclophosphamide
4 cycles of doxorubicin + cyclophosphamide followed by 4 cycles of paclitaxel + pazopanib.
Drug: paclitaxel + pazopanib
4 cycles of paclitaxel + pazopanib
Procedure: surgery
neoadjuvant surgery for breast cancer
Drug: pazopanib monotherapy
6 months of treatment with pazopanib monotherapy
Study Arm (s)Experimental: Treatment Arm
Preoperative
Cycles 1-4 Doxorubicin 60 mg/m2 IV over 15 minutes + Cyclophosphamide 600 mg/m2 IV over 30 minutes of Day 1 every 21 days
followed by:
Cycles 5-8 Paclitaxel 80 mg/m2 IV over 60 minutes (Days 1, 8, and 15) every 28 days in combination with pazopanib (800 mg) PO once daily (2 tablets taken at the same time each day either 1 hour before or 2 hours after a meal) Daily beginning on Day 1 of the first paclitaxel cycle Until 7 days before surgery
Followed by Surgery
Postoperative Pazopanib 800 mg PO once daily (2 tablets taken at the same time each day either 1 hour before or 2 hours after a meal) Daily beginning 4-6 weeks after surgery 6 months from first postoperative dose

Recruitment Information[ + expand ][ + ]

Recruitment StatusCompleted
Estimated Enrollment101
Estimated Completion DateApril 2013
Estimated Primary Completion DateDecember 2011
Eligibility Criteria
Inclusion Criteria:

- The patient must have consented to participate and must have signed and dated an
appropriate IRB-approved consent form that conforms to federal and institutional
guidelines for the study treatment and submission of tumor and blood samples required
for the FB-6 correlative science studies

- The ECOG performance status must be 0 or 1

- Patients must have the ability to swallow oral medication.

- The diagnosis of invasive adenocarcinoma of the breast must have been made by core
needle biopsy or limited incisional biopsy.

- Patients must have ER analysis performed on the primary tumor prior to randomization.
If ER analysis is negative, then PgR analysis must also be performed. (Patients are
eligible with either hormone receptor-positive or hormone receptor-negative tumors.)

- Patients must have clinical stage IIIA, IIIB, or IIIC disease with a mass in the
breast or axilla measuring at least 2.0 cm by physical exam, unless the patient has
inflammatory breast cancer, in which case measurable disease by physical exam is not
required.

- Adequate organ function

- LVEF assessment by 2-D echocardiogram or MUGA scan performed within 3 months prior to
study entry must be greater or equal to 50% regardless of the facility's LLN.

- ECG performed within 4 weeks before study entry must demonstrate a QTc interval that
is less than or equal to 0.47 seconds.

- The TSH level must be within normal limits for the laboratory.

Exclusion Criteria:

- Tumor that has been determined to be HER2-positive by immunohistochemistry (3+) or by
FISH or CISH (positive for gene amplification), or has been determined to be
HER2-equivocal and the investigator plans to administer trastuzumab or other targeted
therapy.

- FNA alone to diagnose the primary breast cancer.

- Excisional biopsy or lumpectomy performed prior to study entry.

- Surgical axillary staging procedure prior to study entry.

- Definitive clinical or radiologic evidence of metastatic disease.

- History of ipsilateral invasive breast cancer regardless of treatment or ipsilateral
DCIS treated with RT.

- Contralateral invasive breast cancer at any time.

- Non-breast malignancies unless the patient is considered to be disease-free for 5 or
more years prior to study entry and is deemed by her physician to be at low risk for
recurrence. Patients with the following cancers are eligible if diagnosed and
treated within the past 5 years: carcinoma in situ of the cervix, carcinoma in situ
of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the
skin.

- Requirement for chronic use of any of the prohibited medications or substances

- Previous therapy with anthracyclines, taxanes, or pazopanib for any malignancy.

- Treatment including RT, chemotherapy, and/or targeted therapy, administered for the
currently diagnosed breast cancer prior to study entry.

- Continued therapy with any hormonal agent such as raloxifene, tamoxifen, or other
SERM.

- Any sex hormonal therapy, e.g., birth control pills and ovarian hormone replacement
therapy

- History of hepatitis B or C.

- Symptomatic pancreatitis or asymptomatic greater or equal to grade 2 elevation of
amylase or lipase as per NCI CTCAE v3.0.

- History of documented pancreatitis.

- Uncontrolled hypertension defined as systolic BP greater than 140 mmHg or diastolic
BP greater greater than 90 mmHg, with or without anti-hypertensive medication.

- History of hypertensive crisis or hypertensive encephalopathy.

- Cardiac disease that would preclude the use of any of the drugs included in the FB-6
treatment regimen.

- History of TIA or CVA.

- History of any arterial thrombotic event within 12 months prior to study entry.

- Pulmonary embolism or DVT within 6 months prior to study entry.

- Symptomatic peripheral vascular disease.

- Any significant bleeding within 6 months prior to study entry, exclusive of
menorrhagia in premenopausal women.

- Known bleeding diathesis, coagulopathy, or requirement for therapeutic doses of
coumadin.

- Serious or non-healing wound, skin ulcers, or bone fracture.

- Gastroduodenal ulcer(s) determined by endoscopy to be active.

- History of GI perforation, abdominal fistulae, or intra-abdominal abscess.

- Malabsorption syndrome, ulcerative colitis, inflammatory bowel disease, resection of
the stomach or small bowel, or other disease significantly affecting gastrointestinal
function.

- Sensory/motor neuropathy greater or equal to grade 2, as defined by the NCI's CTCAE
v3.0.

- Conditions that would prohibit intermittent administration of corticosteroids for
paclitaxel premedication.

- Anticipation of need for major surgical procedures (other than the required breast
surgery) during the course of study therapy and for at least 3 months following the
last dose of pazopanib.

- Pregnancy or lactation at the time of study entry.

- Other nonmalignant systemic disease that would preclude the patient from receiving
study treatment or would prevent required follow-up.

- Known immediate or delayed hypersensitivity reaction to doxorubicin,
cyclophosphamide, paclitaxel, pazopanib, or drugs chemically related to pazopanib.

- Use of any investigational agent within 4 weeks prior to enrollment in the study.
GenderFemale
Ages18 Years
Accepts Healthy VolunteersNo
ContactsNot Provided
Location CountriesUnited States, Canada

Administrative Information[ + expand ][ + ]

NCT Number NCT00849472
Other Study ID Numbers110264
Has Data Monitoring CommitteeNo
Information Provided ByGlaxoSmithKline
Study SponsorGlaxoSmithKline
CollaboratorsNational Surgical Adjuvant Breast and Bowel Project (NSABP)
Investigators Study Director: GSK Clinical Trials GlaxoSmithKline
Verification DateDecember 2013

Locations[ + expand ][ + ]

GSK Investigational Site
Decatur, Alabama, United States, 35601
GSK Investigational Site
Huntsville, Alabama, United States, 35801
GSK Investigational Site
Huntsville, Alabama, United States, 35805
GSK Investigational Site
Antioch, California, United States, 94531
GSK Investigational Site
Fremont, California, United States, 94538
GSK Investigational Site
Hayward, California, United States, 94545
GSK Investigational Site
Oakland, California, United States, 94611
GSK Investigational Site
Redwood City, California, United States, 94063
GSK Investigational Site
Richmond, California, United States, 94801
GSK Investigational Site
Roseville, California, United States, 95661
GSK Investigational Site
Sacramento, California, United States, 95825
GSK Investigational Site
Sacramento, California, United States, 95823
GSK Investigational Site
San Francisco, California, United States, 94115
GSK Investigational Site
San Jose, California, United States, 95119-1110
GSK Investigational Site
San Rafael, California, United States, 94903
GSK Investigational Site
Santa Clara, California, United States, 95051
GSK Investigational Site
Santa Rosa, California, United States, 95403-2192
GSK Investigational Site
South San Francisco, California, United States, 94080
GSK Investigational Site
Stockton, California, United States, 95210
GSK Investigational Site
Vacaville, California, United States, 95688
GSK Investigational Site
Vallejo, California, United States, 94589
GSK Investigational Site
Walnut Creek, California, United States, 94596
GSK Investigational Site
Colorado Springs, Colorado, United States, 80907
GSK Investigational Site
Denver, Colorado, United States, 80218
GSK Investigational Site
Denver, Colorado, United States, 80224
GSK Investigational Site
Denver, Colorado, United States, 80205
GSK Investigational Site
Denver, Colorado, United States, 80210
GSK Investigational Site
Denver, Colorado, United States, 80244
GSK Investigational Site
Englewood, Colorado, United States, 80113
GSK Investigational Site
Greeley, Colorado, United States, 80631
GSK Investigational Site
Lafayette, Colorado, United States, 80026
GSK Investigational Site
Wheat Ridge, Colorado, United States, 80333
GSK Investigational Site
Wheat Ridge, Colorado, United States, 80033
GSK Investigational Site
Fernandina Beach, Florida, United States, 32034
GSK Investigational Site
Gainesville, Florida, United States, 32610
GSK Investigational Site
Jacksonville, Florida, United States, 32258
GSK Investigational Site
Jacksonville, Florida, United States, 32205
GSK Investigational Site
Jacksonville, Florida, United States, 32256
GSK Investigational Site
Jacksonville, Florida, United States, 32207
GSK Investigational Site
Orange Park, Florida, United States, 32073
GSK Investigational Site
Savannah, Georgia, United States, 31404
GSK Investigational Site
Savannah, Georgia, United States, 31405
GSK Investigational Site
Honolulu, Hawaii, United States, 96819
GSK Investigational Site
Iowa City, Iowa, United States, 52242
GSK Investigational Site
Jeffersonville, Kentucky, United States, 47130
GSK Investigational Site
Louisville, Kentucky, United States, 40217
GSK Investigational Site
Louisville, Kentucky, United States, 40207
GSK Investigational Site
Louisville, Kentucky, United States
GSK Investigational Site
Louisville, Kentucky, United States, 40202
GSK Investigational Site
Baltimore, Maryland, United States, 21237
GSK Investigational Site
Ann Arbor, Michigan, United States, 48106
GSK Investigational Site
Battle Creek, Michigan, United States, 49016
GSK Investigational Site
Brighton, Michigan, United States, 48114
GSK Investigational Site
Byron Center, Michigan, United States, 49519
GSK Investigational Site
Dearborn, Michigan, United States, 48123
GSK Investigational Site
Dearborn, Michigan, United States, 48162
GSK Investigational Site
Detroit, Michigan, United States, 48236
GSK Investigational Site
Flint, Michigan, United States, 48532
GSK Investigational Site
Flint, Michigan, United States, 48502
GSK Investigational Site
Flint, Michigan, United States, 48503
GSK Investigational Site
Grand Rapids, Michigan, United States, 49503
GSK Investigational Site
Grosse Point Woods, Michigan, United States, 19229
GSK Investigational Site
Lansing, Michigan, United States, 48910
GSK Investigational Site
Lansing, Michigan, United States, 48912
GSK Investigational Site
Livonia, Michigan, United States, 48154
GSK Investigational Site
Mt. Clemens, Michigan, United States, 48043
GSK Investigational Site
Muskegon, Michigan, United States, 49444
GSK Investigational Site
Port Huron, Michigan, United States, 48060
GSK Investigational Site
Saginaw, Michigan, United States, 48601
GSK Investigational Site
Traverse City, Michigan, United States, 49684
GSK Investigational Site
Warren, Michigan, United States, 48093
GSK Investigational Site
Brunsville, Minnesota, United States, 55337
GSK Investigational Site
Edina, Minnesota, United States, 55435
GSK Investigational Site
Fridley, Minnesota, United States, 55432
GSK Investigational Site
Maplewood, Minnesota, United States, 55109
GSK Investigational Site
Minneapolis, Minnesota, United States, 55433
GSK Investigational Site
Minneapolis, Minnesota, United States, 55454
GSK Investigational Site
Saint Paul, Minnesota, United States, 55101
GSK Investigational Site
St. Louis Park, Minnesota, United States, 55416
GSK Investigational Site
St. Paul, Minnesota, United States, 55102
GSK Investigational Site
Woodbury, Minnesota, United States, 55125
GSK Investigational Site
New Brunswick, New Jersey, United States, 08901
GSK Investigational Site
Stony Brook, New York, United States, 11794
GSK Investigational Site
Charlotte, North Carolina, United States, 28204
GSK Investigational Site
Charlotte, North Carolina, United States, 28211
GSK Investigational Site
Charlotte, North Carolina, United States, 28210
GSK Investigational Site
Charlotte, North Carolina, United States, 28203
GSK Investigational Site
Charlotte, North Carolina, United States, 28262
GSK Investigational Site
Clinton, North Carolina, United States, 28328
GSK Investigational Site
Goldsboro, North Carolina, United States, 27534
GSK Investigational Site
Greenville, North Carolina, United States, 27834
GSK Investigational Site
Wilson, North Carolina, United States, 27893
GSK Investigational Site
Winston-Salem, North Carolina, United States, 27157
GSK Investigational Site
Winston-Salem, North Carolina, United States, 27014
GSK Investigational Site
Canton, Ohio, United States, 44710
GSK Investigational Site
Chargrin, Ohio, United States, 44122
GSK Investigational Site
Clevand, Ohio, United States, 44106
GSK Investigational Site
Dayton, Ohio, United States, 45331
GSK Investigational Site
Dayton, Ohio, United States, 45429
GSK Investigational Site
Dayton, Ohio, United States, 45415
GSK Investigational Site
Kettering, Ohio, United States, 45409
GSK Investigational Site
Kettering, Ohio, United States, 45429
GSK Investigational Site
Lebanon, Ohio, United States, 45036
GSK Investigational Site
Mentor, Ohio, United States, 44060
GSK Investigational Site
Middletown, Ohio, United States, 45042
GSK Investigational Site
Westlake, Ohio, United States, 44145
GSK Investigational Site
Wilminton, Ohio, United States, 45042
GSK Investigational Site
Xenia, Ohio, United States, 45385
GSK Investigational Site
Portland, Oregon, United States, 97225
GSK Investigational Site
Portland, Oregon, United States
GSK Investigational Site
Portland, Oregon, United States, 97213
GSK Investigational Site
Ephrata, Pennsylvania, United States, 17522
GSK Investigational Site
Greensburg, Pennsylvania, United States, 15601
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19141
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19107
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19115
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15215
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15237
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15212
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15232
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15213
GSK Investigational Site
West Reading, Pennsylvania, United States, 19611
GSK Investigational Site
Lubbock, Texas, United States, 79410
GSK Investigational Site
Richmond, Virginia, United States, 23298
GSK Investigational Site
Richmond, Virginia, United States, 23235
GSK Investigational Site
Seattle, Washington, United States, 98101
GSK Investigational Site
Vancouver, Washington, United States, 98668
GSK Investigational Site
Vancover, Washington, United States, 98684
GSK Investigational Site
Chippewa Falls, Wisconsin, United States, 54729
GSK Investigational Site
Eau Claire, Wisconsin, United States, 54701
GSK Investigational Site
Marshfield, Wisconsin, United States, 54449
GSK Investigational Site
Minocqua, Wisconsin, United States, 54548
GSK Investigational Site
Rhinelander, Wisconsin, United States, 54501
GSK Investigational Site
Rice Lake, Wisconsin, United States, 54868
GSK Investigational Site
Stevens Point, Wisconsin, United States, 54481
GSK Investigational Site
Weston, Wisconsin, United States, 54476
GSK Investigational Site
Wisconsin Rapids, Wisconsin, United States, 54494
GSK Investigational Site
Ottawa, Ontario, Canada, K1H 8L6
GSK Investigational Site
Montreal, Quebec, Canada, H3G 1A4
GSK Investigational Site
Montreal, Quebec, Canada, H3A 1A1
GSK Investigational Site
Montreal, Quebec, Canada, H2L 4M1
GSK Investigational Site
Montreal, Quebec, Canada, H3T 1E2
GSK Investigational Site
Quebec, Canada, G1S 4L8